SF
Security Financial Services, INC.
13F filer · CIK 0001913590Reported Jul 15, 2026
Net buyer this quarter
13F portfolio value$721MU.S. long equity reported on 13F
Positions7711 new · 8 closed
Net flow last quarter+$589KBuys minus sells
Top 10 positions weight8.3%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026Reported Jul 15, 202677 positions | |||||
| $13.2M | 1.83% | 0.00% | +1.9% | Q4 2021 | |
| $11.5M | 1.59% | 3.37% | -25.2% | Q1 2025 | |
| $9.7M | 1.35% | 0.15% | +16.5% | Q3 2025 | |
| $4.32M | 0.60% | Not reported | +0.9% | Q4 2021 | |
| $4.05M | 0.56% | 0.01% | +13.9% | Q4 2024 | |
| $4.01M | 0.56% | 0.00% | +3.8% | Q4 2021 | |
| $3.86M | 0.54% | 0.54% | +104.2% | Q1 2025 | |
| $3.73M | 0.52% | 0.00% | -4.5% | Q4 2021 | |
| $2.71M | 0.38% | 0.00% | +9.6% | Q2 2023 | |
| $2.56M | 0.36% | 0.00% | +5.9% | Q4 2021 | |
| $2.05M | 0.28% | 0.00% | +6.2% | Q2 2023 | |
| $1.82M | 0.25% | Not reported | -8.2% | Q2 2023 | |
| $1.72M | 0.24% | Not reported | -0.3% | Q4 2021 | |
| $1.63M | 0.23% | Not reported | -51.8% | Q4 2023 | |
| $1.62M | 0.22% | 0.00% | +0.3% | Q4 2021 | |
| $1.61M | 0.22% | 0.00% | +10.6% | Q2 2023 | |
| $1.56M | 0.22% | 0.00% | +1.8% | Q4 2021 | |
| $1.52M | 0.21% | 0.20% | +0.7% | Q4 2021 | |
| $1.46M | 0.20% | 0.00% | -1.4% | Q4 2021 | |
| PBPMBSPuramed Bioscience Inc. | $1.35M | 0.19% | 0.01% | -2.7% | Q3 2025 |
| $1.18M | 0.16% | 0.00% | -1.1% | Q4 2021 | |
| $1.11M | 0.15% | 0.00% | +1.5% | Q4 2021 | |
| $1.1M | 0.15% | Not reported | +4.0% | Q4 2021 | |
| $971K | 0.13% | 0.00% | +17.5% | Q4 2021 | |
| $952K | 0.13% | Not reported | +0.8% | Q4 2021 | |
| $925K | 0.13% | 0.00% | +3.2% | Q4 2021 | |
| $873K | 0.12% | 0.00% | +1.0% | Q2 2024 | |
| $721K | 0.10% | 0.00% | +10.0% | Q3 2024 | |
| $720K | 0.10% | 0.00% | +2.2% | Q4 2021 | |
| $696K | 0.10% | 0.00% | +1.4% | Q1 2022 | |
| $682K | 0.09% | Not reported | +12.6% | Q2 2025 | |
| $681K | 0.09% | 0.00% | +1.2% | Q4 2021 | |
| $621K | 0.09% | Not reported | -5.6% | Q2 2025 | |
| $616K | 0.09% | 0.00% | +0.5% | Q4 2021 | |
| $603K | 0.08% | 0.00% | -5.3% | Q4 2021 | |
| $598K | 0.08% | 0.00% | -16.3% | Q4 2021 | |
| $570K | 0.08% | Not reported | +9.5% | Q2 2023 | |
| $529K | 0.07% | 0.00% | 0.0% | Q4 2021 | |
| $527K | 0.07% | 0.00% | +3.6% | Q3 2024 | |
| $504K | 0.07% | 0.00% | New | Q2 2026 | |
| $498K | 0.07% | 0.00% | -8.5% | Q4 2021 | |
| $495K | 0.07% | 0.00% | -12.9% | Q4 2021 | |
| $453K | 0.06% | 0.00% | +0.3% | Q4 2021 | |
| $438K | 0.06% | 0.00% | +1.3% | Q4 2021 | |
| $424K | 0.06% | 0.00% | +1.7% | Q1 2026 | |
| $410K | 0.06% | 0.00% | +2.2% | Q2 2023 | |
| $383K | 0.05% | 0.00% | New | Q2 2026 | |
| $377K | 0.05% | 0.00% | +8.7% | Q3 2025 | |
| $373K | 0.05% | 0.00% | Not reported | Q1 2025 | |
| $349K | 0.05% | 0.00% | +4.9% | Q4 2021 | |
| Q1 2026Reported May 27, 202674 positions | |||||
| $12.9M | 2.04% | 4.51% | +2.4% | Q1 2025 | |
| $11.3M | 1.79% | 0.00% | +2.1% | Q4 2021 | |
| $9.89M | 1.56% | 0.13% | +45.7% | Q3 2025 | |
| $4.15M | 0.66% | 0.01% | -67.7% | Q4 2024 | |
| $3.73M | 0.59% | Not reported | -1.0% | Q4 2021 | |
| $3.47M | 0.55% | 0.00% | -0.6% | Q4 2021 | |
| $2.6M | 0.41% | Not reported | -34.5% | Q4 2023 | |
| $2.6M | 0.41% | 0.00% | +1.6% | Q4 2021 | |
| $2.4M | 0.38% | 0.00% | -2.0% | Q4 2021 | |
| $2.16M | 0.34% | 0.00% | +5.7% | Q2 2023 | |
| $1.99M | 0.32% | Not reported | -41.8% | Q2 2023 | |
| $1.63M | 0.26% | 0.00% | -14.6% | Q4 2021 | |
| $1.59M | 0.25% | Not reported | -0.3% | Q4 2021 | |
| $1.58M | 0.25% | 0.00% | -0.5% | Q2 2023 | |
| $1.52M | 0.24% | 0.20% | +3.1% | Q4 2021 | |
| $1.4M | 0.22% | 0.00% | +0.1% | Q4 2021 | |
| PBPMBSPuramed Bioscience Inc. | $1.39M | 0.22% | 0.01% | +41.1% | Q3 2025 |
| $1.34M | 0.21% | 0.27% | +26.8% | Q1 2025 | |
| $1.18M | 0.19% | 0.00% | +2.0% | Q4 2021 | |
| $1.17M | 0.19% | 0.00% | +14.1% | Q2 2023 | |
| $1.11M | 0.18% | 0.00% | +7.2% | Q4 2021 | |
| $1.01M | 0.16% | Not reported | +2.2% | Q4 2021 | |
| $932K | 0.15% | 0.00% | +0.3% | Q4 2021 | |
| $829K | 0.13% | 0.00% | +2.2% | Q4 2021 | |
| $766K | 0.12% | Not reported | -2.7% | Q4 2021 | |
| $722K | 0.11% | 0.00% | +9.7% | Q4 2021 | |
| $704K | 0.11% | 0.00% | -26.8% | Q4 2021 | |
| $660K | 0.10% | 0.00% | +6.0% | Q1 2022 | |
| $652K | 0.10% | 0.00% | -27.6% | Q4 2021 | |
| $642K | 0.10% | 0.00% | +1.7% | Q2 2024 | |
| $639K | 0.10% | 0.00% | -14.5% | Q4 2021 | |
| $610K | 0.10% | Not reported | +2.3% | Q2 2025 | |
| $607K | 0.10% | Not reported | +24.7% | Q2 2025 | |
| $580K | 0.09% | 0.00% | +2.4% | Q4 2021 | |
| $580K | 0.09% | 0.00% | +6.6% | Q3 2024 | |
| $574K | 0.09% | 0.00% | +7.2% | Q4 2021 | |
| $536K | 0.08% | 0.00% | -2.6% | Q4 2021 | |
| $529K | 0.08% | Not reported | -2.6% | Q2 2023 | |
| $497K | 0.08% | 0.00% | -1.1% | Q4 2021 | |
| $475K | 0.08% | 0.00% | -4.8% | Q1 2025 | |
| $465K | 0.07% | 0.00% | -4.5% | Q3 2024 | |
| $402K | 0.06% | 0.00% | -1.5% | Q4 2021 | |
| $379K | 0.06% | 0.00% | +50.2% | Q3 2025 | |
| $375K | 0.06% | 0.00% | -8.9% | Q2 2023 | |
| $359K | 0.06% | 0.00% | +11.3% | Q4 2021 | |
| $320K | 0.05% | 0.00% | +0.2% | Q4 2021 | |
| $318K | 0.05% | 0.00% | -32.7% | Q4 2021 | |
| $309K | 0.05% | 0.00% | +2.8% | Q4 2021 | |
| $300K | 0.05% | 0.00% | +6.1% | Q3 2025 | |
| $289K | 0.05% | 0.00% | +5.0% | Q3 2025 | |
| Q4 2025Reported Jan 27, 202687 positions | |||||
| $13.4M | 2.10% | 4.40% | +2.2% | Q1 2025 | |
| $11.9M | 1.87% | 0.00% | +0.4% | Q4 2021 | |
| $11.9M | 1.86% | 0.02% | -6.9% | Q4 2024 | |
| $6.21M | 0.97% | 0.09% | -11.0% | Q3 2025 | |
| $3.95M | 0.62% | Not reported | -3.1% | Q4 2021 | |
| $3.82M | 0.60% | 0.00% | +0.5% | Q4 2021 | |
| $3.67M | 0.58% | Not reported | +25.5% | Q4 2023 | |
| $3.44M | 0.54% | Not reported | -61.7% | Q2 2023 | |
| $3.2M | 0.50% | 0.00% | +1.6% | Q4 2021 | |
| $2.18M | 0.34% | 0.00% | -0.7% | Q2 2023 | |
| $2.07M | 0.32% | 0.00% | +0.5% | Q4 2021 | |
| $1.78M | 0.28% | 0.00% | +0.4% | Q2 2023 | |
| $1.71M | 0.27% | 0.00% | -27.6% | Q4 2021 | |
| $1.54M | 0.24% | Not reported | Not reported | Q4 2021 | |
| $1.48M | 0.23% | 0.20% | +11.3% | Q4 2021 | |
| $1.41M | 0.22% | 0.00% | Not reported | Q4 2021 | |
| $1.35M | 0.21% | 0.00% | +2.1% | Q4 2021 | |
| $1.16M | 0.18% | 0.21% | +208.0% | Q1 2025 | |
| $1.12M | 0.18% | 0.00% | +3.4% | Q2 2023 | |
| $1.04M | 0.16% | Not reported | +1.3% | Q4 2021 | |
| $990K | 0.16% | 0.00% | -2.1% | Q4 2021 | |
| PBPMBSPuramed Bioscience Inc. | $986K | 0.15% | 0.01% | +99.2% | Q3 2025 |
| $953K | 0.15% | 0.00% | 0.0% | Q4 2021 | |
| $881K | 0.14% | 0.00% | +5.3% | Q4 2021 | |
| $875K | 0.14% | 0.00% | +10.5% | Q4 2021 | |
| $862K | 0.14% | Not reported | +4.0% | Q4 2021 | |
| $832K | 0.13% | 0.00% | -0.2% | Q4 2021 | |
| $736K | 0.12% | 0.00% | +4.4% | Q4 2021 | |
| $730K | 0.11% | 0.00% | -1.9% | Q4 2021 | |
| $692K | 0.11% | 0.00% | +4.6% | Q4 2021 | |
| $657K | 0.10% | 0.00% | +4.3% | Q3 2024 | |
| $627K | 0.10% | Not reported | +7.1% | Q2 2023 | |
| $551K | 0.09% | Not reported | +2.6% | Q2 2025 | |
| $528K | 0.08% | 0.00% | +15.0% | Q1 2022 | |
| $495K | 0.08% | 0.00% | +4.5% | Q4 2021 | |
| $494K | 0.08% | 0.00% | -69.1% | Q4 2021 | |
| $494K | 0.08% | Not reported | +9.3% | Q2 2025 | |
| $492K | 0.08% | 0.00% | +3.0% | Q4 2021 | |
| $486K | 0.08% | 0.00% | -2.6% | Q3 2023 | |
| $484K | 0.08% | 0.00% | -3.6% | Q1 2024 | |
| $473K | 0.07% | 0.00% | +7.9% | Q2 2024 | |
| $472K | 0.07% | 0.00% | +5.0% | Q3 2024 | |
| $472K | 0.07% | 0.00% | +5.0% | Q1 2025 | |
| $463K | 0.07% | 0.00% | -4.7% | Q1 2024 | |
| $447K | 0.07% | 0.00% | +16.8% | Q4 2021 | |
| $432K | 0.07% | 0.00% | -3.7% | Q1 2024 | |
| $426K | 0.07% | 0.00% | -4.8% | Q4 2023 | |
| $417K | 0.07% | 0.00% | -5.5% | Q2 2023 | |
| $401K | 0.06% | 0.00% | +0.2% | Q4 2021 | |
| $399K | 0.06% | 0.00% | -2.3% | Q4 2023 | |
| Q3 2025Reported Oct 14, 202585 positions | |||||
| $12.9M | 2.08% | 4.30% | +3.4% | Q1 2025 | |
| $11.4M | 1.84% | 0.02% | +33.9% | Q4 2024 | |
| $11.1M | 1.79% | 0.00% | +1.3% | Q4 2021 | |
| $9.01M | 1.46% | Not reported | +1.7% | Q2 2023 | |
| $7.56M | 1.22% | 0.10% | New | Q3 2025 | |
| $3.98M | 0.64% | Not reported | -3.0% | Q4 2021 | |
| $3.73M | 0.60% | 0.00% | +36.7% | Q4 2021 | |
| $3.37M | 0.55% | 0.00% | +2.3% | Q4 2021 | |
| $2.71M | 0.44% | Not reported | Not reported | Q4 2023 | |
| $2.2M | 0.36% | 0.00% | -24.3% | Q2 2023 | |
| $2.18M | 0.35% | 0.00% | +2.1% | Q4 2021 | |
| $1.71M | 0.28% | 0.00% | +2.1% | Q4 2021 | |
| $1.69M | 0.27% | 0.00% | -0.9% | Q2 2023 | |
| $1.64M | 0.26% | 0.00% | +0.1% | Q4 2021 | |
| $1.59M | 0.26% | 0.00% | +1.8% | Q4 2021 | |
| $1.48M | 0.24% | Not reported | -0.1% | Q4 2021 | |
| $1.46M | 0.24% | 0.00% | -15.0% | Q4 2021 | |
| $1.33M | 0.22% | 0.18% | -0.1% | Q4 2021 | |
| $1.03M | 0.17% | Not reported | -1.3% | Q4 2021 | |
| $1.02M | 0.17% | 0.00% | +5.9% | Q4 2021 | |
| $938K | 0.15% | 0.00% | +1.7% | Q4 2021 | |
| $850K | 0.14% | 0.00% | -0.9% | Q4 2021 | |
| $840K | 0.14% | 0.00% | +4.2% | Q2 2023 | |
| $817K | 0.13% | 0.00% | +0.2% | Q4 2021 | |
| $816K | 0.13% | 0.00% | -1.4% | Q4 2021 | |
| $737K | 0.12% | 0.04% | Not reported | Q4 2021 | |
| $708K | 0.11% | 0.00% | +1.9% | Q4 2021 | |
| $660K | 0.11% | 0.00% | +3.2% | Q4 2021 | |
| $652K | 0.11% | 0.00% | +2.1% | Q4 2021 | |
| $651K | 0.11% | Not reported | +17.8% | Q2 2023 | |
| $643K | 0.10% | Not reported | -0.1% | Q4 2021 | |
| $630K | 0.10% | 0.00% | +3.0% | Q4 2021 | |
| $623K | 0.10% | 0.00% | +0.9% | Q3 2024 | |
| $558K | 0.09% | 0.00% | +9.5% | Q4 2021 | |
| $510K | 0.08% | Not reported | +57.8% | Q2 2025 | |
| PBPMBSPuramed Bioscience Inc. | $495K | 0.08% | 0.01% | New | Q3 2025 |
| $474K | 0.08% | 0.00% | +4.7% | Q2 2023 | |
| $455K | 0.07% | 0.00% | +9.9% | Q3 2024 | |
| $453K | 0.07% | 0.00% | +3.6% | Q4 2021 | |
| $453K | 0.07% | Not reported | +74.3% | Q2 2025 | |
| $450K | 0.07% | 0.00% | Not reported | Q1 2024 | |
| $444K | 0.07% | Not reported | +28.8% | Q1 2023 | |
| $442K | 0.07% | 0.00% | +4.7% | Q4 2021 | |
| $432K | 0.07% | 0.00% | -41.5% | Q4 2021 | |
| $430K | 0.07% | 0.00% | -0.5% | Q3 2023 | |
| $426K | 0.07% | 0.00% | +3.4% | Q1 2024 | |
| $424K | 0.07% | 0.00% | +8.2% | Q3 2024 | |
| $421K | 0.07% | 0.00% | -3.3% | Q4 2023 | |
| $421K | 0.07% | 0.00% | -9.0% | Q1 2024 | |
| $414K | 0.07% | 0.00% | +2.6% | Q4 2023 | |
Premium opens every quarter this fund has filed